ERBB2 and breast carcinoma: Previous studies on somatic mutations in the her2 gene, in human breast cancer patients, revealed several mutations associated with resistance to therapy and/or specific clinicopathological features, reported in National Cancer Institute, International Cancer Genome Consortium and COSMIC databases.